Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Rani Therapeutics Holdings, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
Docs: "Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update - Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 - Presentation of late-breaking abstract on oral delivery of GLP-1 agonist at American Diabetes Association’s Scientific Sessions - Plan to initiate Phase 2 study for RT-102 and Phase 1study for RT-111 in 2H of 2023 SAN JOSE, Calif., August 11, 2023"
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update - Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing a biosimilar for the monoclonal antibody ustekinumab - - Received preliminary feedback from FDA on RT-102 development plans; 505 pathway for RT-102 could be suitable - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2H of 2023 - SAN JOSE, Calif., May 10, 2023"
04/05/2023 8-K Other Events  Interactive Data
03/22/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/22/2023 10-K Annual Report for the period ended December 31, 2022
03/22/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update - Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis - - Received preliminary feedback from FDA on RT-102 development plans; 505 pathway for RT-102 could be suitable - - Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing an ustekinumab biosimilar - - Conference call and webcast today at 4:30 p.m. ET - SAN JOSE, Calif., March 22, 2023"
03/15/2023 SC 13D/A South Lake One LLC reports a 27.2% stake in Rani Therapeutics Holdings, Inc.
01/09/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
01/05/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update - Preliminary feedback from FDA on RT-102 development plans; 505 pathway for RT-102 could be suitable - - Multiple anticipated clinical milestones expected in 2023, including initiation of Phase 2 study of RT-102 in osteoporosis - SAN JOSE, Calif., January 5, 2023"
12/30/2022 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ...
12/30/2022 EFFECT Form EFFECT - Notice of Effectiveness:
12/29/2022 424B7 Form 424B7 - Prospectus [Rule 424(b)(7)]:
12/16/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
12/06/2022 8-K Investor presentation
Docs: "Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1study - RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1study - - Repeat doses of RT-102 were generally well tolerated, with no serious adverse events - - RaniPill™ GO delivered PTH to subjects with a 91% success rate and demonstrated high bioavailability - - Data from Part 1 and Part 2 of the Phase 1study of RT-102 support advancement to a Phase 2 study – SAN JOSE, Calif., December 6, 2022",
"RT-102 Phase I Study"
10/24/2022 8-K Quarterly results
08/25/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Controlled EquitySM Sales Agreement, by and among Rani Therapeutics Holdings, Inc., and Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC",
"Opinion of Cooley LLP"
08/25/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/11/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/10/2022 8-K Quarterly results
Docs: "Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update - Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis - - Anticipate initiating an additional Phase 1 clinical trial in 2H 2022 - - Capitalized to fund operations into mid-2024 - SAN JOSE, Calif., August 10, 2022"
08/08/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "FORM 8-K"
08/01/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/26/2022 8-K Quarterly results
05/11/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/11/2022 8-K Quarterly results
04/13/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/13/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/31/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/30/2022 10-K Annual Report for the period ended December 31, 2021
03/29/2022 8-K Quarterly results
03/23/2022 8-K Quarterly results
02/23/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Rani Therapeutics Unveils High-Capacity RaniPill ™ Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results",
"Presentation dated February 2022"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy